HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Advertisers Using Browsing Data To Target Ads Warned To Be Sure Consumers Have Control

Executive Summary

BBB National Programs' Digital Advertising Accountability Program publishes compliance warning reminding businesses that consumers must have control over interest-based advertising, driven by data websites collect. For certain categories of sensitive information, websites should only use the information when consumers opt-in.

You may also be interested in...



Industry Self-Regulation Reviews Show Influencers Aren’t Ad Claim Compliance Experts

Sustainability claims are growing as targets of reviews by BBB National Programs investigative divisions, which also anticipate more ad violations from online dark patterns in 2022.

‘Dark Patterns’ Casting Shadow On E-commerce

Dark patterns, a “kind of a scary new phrase,” are “design choices that that manipulate users on a website into making choices that they wouldn't otherwise make,” says advertising law attorney Amy Ralph Mudge.

HBW US Executive Decisions: Engle Leaves FTC, Changes At Nature's Bounty, CRN And Benev

Mary Engle led FTC enforcement actions including against POM Wonderful’s claims for its pomegranate supplements; Huber is CRN’s scientific and regulatory affairs VP and Amanda Darlington is government relations director; Jones takes charge of Nature’s Bounty supply chain; and Benev Co. names five aesthetic experts to Medical Advisory Board to advance its “medically developed cosmeceutical line.”

Topics

Latest News
UsernamePublicRestriction

Register

RS152652

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel